Research programme: antibacterial and antiviral therapeutics - BioSource Pharm

Drug Profile

Research programme: antibacterial and antiviral therapeutics - BioSource Pharm

Alternative Names: BSP-123A; BSP-C812; BSPC-705 antibiotics; BSPC-728 antibiotics; BSPC-801 antibiotics

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator BioSource Pharm
  • Class Lipopeptides; Macrolides; Polymixins; Sulfonamides
  • Mechanism of Action Cell wall inhibitors; Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Bacterial infections

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Bacterial-infections in USA
  • 20 Jan 2011 Preclinical development is ongoing in USA
  • 20 Jan 2011 Antibacterial therapeutics are available for licensing as of 20 Jan 2011. http://www.biosourcepharm.com/
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top